Navigation Links
More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms
Date:3/12/2008

MADISON, N.J., March 12 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it would need to conduct additional clinical studies to address questions from the Committee for Medicinal Products for Human Use (CHMP) regarding the risk-benefit profile of desvenlafaxine as a treatment for vasomotor symptoms. As a result, Wyeth voluntarily withdrew its application for European Marketing Authorisation for desvenlafaxine for the treatment of vasomotor symptoms (hot flashes) associated with menopause.

"We believe that desvenlafaxine can provide women with a non-hormonal option to treat vasomotor symptoms (VMS), and Wyeth remains committed to developing the molecule for this indication," says Gary L. Stiles, M.D., Executive Vice President and Chief Medical Officer, Wyeth Pharmaceuticals. "Some of the questions raised by the CHMP can be addressed with our planned clinical trials, including the 12-month study Wyeth is initiating with post- menopausal women early this year. The Company also is considering whether to conduct additional studies."

About Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In particular, there can be no assurance that PRISTIQ (desvenlafaxine) will be commercially successful in the highly competitive market for antidepressants in the United States, or that desvenlafaxine will be approved in the future for other indications (including treatment of vasomotor symptoms associated with menopause) and/or in other countries. Other risks and uncertainties include the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and our pipeline products (including future regulatory action regarding our pending applications for desvenlafaxine for the treatment of major depressive disorder and the treatment of vasomotor symptoms, as to which no assurance can be given); government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products (including from clinical trials of desvenlafaxine); the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS." The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen
2. Genetic research unveils common origins for distinct clinical diagnoses
3. Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming SAWC Conference
4. Akela Pharma initiates its first abuse deterrent opioid Phase I clinical trial
5. Sensor necklace aims to increase elderly and clinical trial participant drug compliance
6. Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance
7. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
8. Crdentia Appoints Randall Turnbull to Senior Vice President and Chief Clinical Officer
9. Clinical depression raises risk of death for heart attack patients years after attack
10. IAVI and VaxDesign partner to develop a clinical trial in a test tube for AIDS vaccines
11. Skin Friendly Releases Clinically Proven Hypoallergenic Anti-Bacterial Barrier Lotion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , ... January 16, 2017 , ... San Francisco dentist, ... Element, the latest in 3-D scanning device which is capable of taking digital impressions ... advances in dentistry, such as CAD CAM restorations , in terms of speed, ...
(Date:1/16/2017)... ... 16, 2017 , ... NexTec Group has been selected as a member of ... their accomplishments in the field of midmarket financial software. , Members of the VAR ... Selection is not based on revenue and those firms chosen represent a wide range ...
(Date:1/15/2017)... Ohio (PRWEB) , ... January 15, 2017 , ... ... applications, Gensuite’s Community Outreach is a program that strives to better communities around ... each global locations’ community. It also provides the opportunity for team members to ...
(Date:1/15/2017)... ... January 15, 2017 , ... ... Companies has achieved accreditation for its specialty care services. Albertsons Companies is ... in-house specialty care service for pharmacy patients. , Accreditation by ACHC reflects Albertsons ...
(Date:1/15/2017)... (PRWEB) , ... January 15, 2017 , ... ... choice of best physicians in eight Bay Area counties for 2017. Almost 1,000 ... healthcare research company managing the award process. Results were announced the magazine’s ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... , January 16, 2017 According to a new ... Opportunity Analysis and Industry Forecast, 2014 - 2022," the global antioxidants market generated ... registering a CAGR of 6.42% during the forecast period. In the natural antioxidants ... volume in 2015. Continue Reading ... ...
(Date:1/16/2017)... TORONTO , Jan. 16, 2017  Today, Analytics ... cost-effective medical devices, announced its expansion into JLABS @ ... Johnson Innovation,s life science incubators. As a resident in ... of cardiovascular medical device development and commercialization expertise. ... a life science innovation center that provides a flexible ...
(Date:1/15/2017)... DUBLIN , January 16, 2017 ... produits innovants à base de collagène pour la régénération de ... au poste de directeur général avec effet immédiat. ... Bill est ... qui a occupé plusieurs postes de gestion générale et de ...
Breaking Medicine Technology: